Navigation Links
Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research
Date:5/9/2008

TAMPA, Fla., May 9 /PRNewswire/ -- The Cancer Research Alliance, an organization comprised of 12 of the nation's best cancer centers including Moffitt Cancer Center, is asking all 303 million Americans to exercise their power over cancer by stepping up and donating $1 to cancer research efforts this Mother's Day through Father's Day.

The campaign, dubbed the "Infinite Power of One(TM)" campaign has two key goals: to activate Americans everywhere to take matters into their own hands, join together and exercise their collective power over cancer, and second, to raise much needed dollars to accelerate innovative cancer research at the participating cancer centers.

The public can join the "Infinite Power of One(TM)" campaign by visiting the campaign's sponsor, http://www.celebrations.com from May 11 through June 15 to donate. After donating, each person will be asked to add his or her own photo to the "Infinite Power of One" Healing Mosaic to celebrate the infinite power that one person and one dollar can make on our health. Proceeds will benefit cancer research at all member cancer centers.

Located in Tampa, Florida, Moffitt Cancer Center (http://www.moffitt.org) is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer, as well as for ear, nose and throat. Moffitt's sole mission is to contribute to the prevention and cure of cancer.

ABOUT THE CANCER RESEARCH ALLIANCE

Th
'/>"/>

SOURCE Moffitt Cancer Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening
2. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
3. Fujifilm and the National Breast Cancer Foundation Provide Free Mammograms as Part of Images of Health Campaign
4. European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics Lung Cancer Drug
5. When to Wait and When to Treat? New Program Will Search for Biomarkers in Men With Prostate Cancer to Help Find an Answer
6. HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
7. New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
8. National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients
9. Sale of Colon Cancer Diagnostic Tool to Czech Republic
10. Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research
11. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ -...(the "Company"), a global biopharmaceutical compan... announced that the U.S. Food and Drug Administrat...he Company,s PI3K/Akt pathway inhibitor compound, ...ed/refractory multiple myeloma. Keryx Biopharmaceu...
(Date:12/1/2009)..., INCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-Fir...I ) today announced revenue guidance for the fourt... $57 million, as compared with $69 million for the...r 2008 results was the first of two installment pa...ed in fourth quarter 2008 results was a one-time $...
(Date:12/1/2009)... , CAMBRIDGE, Mass., Dec. 1 /PRNewswire/...ogy industry and to promote its potential, a group...ion of the Synthetic Biology Industry Association ...e goal of the association is to provide a forum fo...the new industry, address its opportunities and it...
(Date:12/1/2009)... , SAN FRANCISCO, Dec. 1 The Bu...most half the value it lost in October. The Select...xcellent month for the general markets with the Do...value. The gains held firm in the final two tradin... sluggish Thanksgiving holiday shopping and Dubai,...
Breaking Biology Technology:AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2Biotech Gets Back on Track in November 2Biotech Gets Back on Track in November 3Biotech Gets Back on Track in November 4
...EAPOLIS, May 19 G. Arthur Herbert, a Techne Corpo...s Audit Committee, Executive Compensation Committe...ed today that he is planning to retire at the end ... shareholders reelect Directors on an annual basis...r re-nomination as a Director for fiscal year 2010...
... ALTO, Calif., May 19 Pioneering medical device c...learance from the U.S. Food and Drug Administratio...ice, the ,Signos,. , , (Photo: http://www.newsco...ics has developed a cost-effective device that for... health professionals to use ultrasound in their c...
...t-in-class Oral Therapeutic for IBD with Novel Mod...ChemoCentryx, Inc., today announced that data from...ed Oral Therapy Evaluation in Crohn,s disease Tria...(CCX282-B) in patients with moderate-to-severe Cro...at the upcoming 2009 Digestive Disease Week (DDW) ...
Other Biology Technology:Techne Corporation Announces the Retirement of G. Arthur Herbert, a Member of Its Board of Directors 2Signostics Receives FDA Clearance for World's Smallest Ultrasound Product 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5
(Date:12/1/2009)... Particularly in Alzheimer,s disease, nerve cell d...ew therapeutic options may possibly be derived fro...sm. These findings have been published in the curr...ence . Until only a few years ago, neurogenesis t...ed to be impossible in the adult brain. The textbo...
(Date:12/1/2009)... Yehezkel Ben-Ari, winner of the 2009 Inserm Grand...ed its commitment to paying tribute to outstanding...ts. By honouring talents, Inserm intends to,demon...lved in today,s biological, medical and,health re...and women who carry out and,drive this research e...
(Date:12/1/2009)... In a world first, a Monash University-led interna...ay to boost the output of the next generation of s...n collaboration with colleagues from the universit...d tandem dye-sensitised solar cells with a three-f...red with previously reported tandem dye-sensitised...
Breaking Biology News(10 mins):New source discovered for the generation of nerve cells in the brain 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3Innovation puts next-generation solar cells on the horizon 2STALLERGENES 3A Strong Sales Growth in 1st Half Year 3A up 12 25 Full Year Guidance Maintained 13049 1STALLERGENES 3A Strong Sales Growth in 1st Half Year 3A up 12 25 Full Year Guidance Maintained 13049 2STALLERGENES 3A Strong Sales Growth in 1st Half Year 3A up 12 25 Full Year Guidance Maintained 13049 3NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 1NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 2NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 3Gene Mutation Is Linked to Heart Muscle Disease 51799 1Gene Mutation Is Linked to Heart Muscle Disease 51799 2
...erence between a lifeless sack of chemicals and a ..., according to Stanford biophysical chemist Steven...y of California-Davis and Lawrence Livermore Natio...ll membranes with unprecedented resolution-on the ...idual molecules but much smaller than entire cells...
... led by scientists at the Broad Institute of MIT a...w kind of genetic "roadmap" that can connect human...ell as predict how new drugs work in human cells. ...s uses are described in the September 29 issue of ...ber 28 immediate early edition of Cancer Cell. The...
...rowing health problem. Giving antioxidants is reco...to control their blood sugar levels. , The herbal..., Silybum marianum (silymarin) is known to have an...eek in Phytotherapy Research shows that this extra...of sugar bound to haemoglobin in blood, as well as...
Other Biology News:With record resolution and sensitivity, tool images how life organizes in a cell membrane 2With record resolution and sensitivity, tool images how life organizes in a cell membrane 3With record resolution and sensitivity, tool images how life organizes in a cell membrane 4With record resolution and sensitivity, tool images how life organizes in a cell membrane 5With record resolution and sensitivity, tool images how life organizes in a cell membrane 6Genetic 'roadmap' charts links between drugs and human disease 2Genetic 'roadmap' charts links between drugs and human disease 3
Mouse Anti-Human Spastin Monoclonal Antibody, Unconjugated, Clone Sp 3G11/1 from Santa Cruz Biotechnology, Inc.
mCD-1 Multi-Probe Template Set from BD Biosciences Pharmingen
Custom Immunization from Proteintech Group, Inc.
Rat Anti-Mouse VCAM-1 / CD106 Monoclonal Antibody, Unconjugated, Clone 112702 from R&D Systems
Biology Products: